Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

A Phase I Study of Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This is a prospective, single-center phase I clinical study aimed at determining the maximum-tolerated dose, recommended phase 2 dose and safety of Lintuzumab-Ac225 in combination with CLAG-M chemotherapy in the management of relapsed/refractory acute myeloid leukemia. This study uses a 3+3 design with a five-patient cohort at the recommended phase 2 dose.

Study Overview

• Status: Active, not recruiting
• Conditions: Acute Myeloid Leukemia
• Intervention / Treatment: Biological: Lintuzumab-Ac-225 (Dose 1: 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab); Drug: Cladribine; Drug: Cytarabine; Drug: Mitoxantrone; Drug: G-CSF; Biological: Lintuzumab-Ac-225 (Dose 2: 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab); Biological: Lintuzumab-Ac-225 (Dose 3: 0.75 μCi/kg with 4.7μg/kg lintuzumab); Biological: Lintuzumab-Ac-225 (Dose 4: 1.00 μCi/kg with 6.4 μg/kg lintuzumab); Biological: Lintuzumab-Ac-225 (Dose 5: 1.25 μCi/kg with 8.0 μg/kg lintuzumab); Biological: Lintuzumab-Ac-225 (Recommended Phase 2 Dose)

Detailed Description

Relapsed/refractory acute myeloid leukemia (RR-AML) in adults is an important therapeutic challenge. Nearly 60% of AML patients ultimately relapse or have refractory disease, and failure to achieve remission in this population is almost universally fatal. Therefore, a critical need exists for the development of novel therapies.

Currently, for RR-AML, many institutions utilize the chemotherapy regimen of CLAG-M (cladribine, cytarabine, G-CSF, mitoxantrone) based on a reported morphological complete remission (CR) rate of 58% in prospective clinical trials. Because of this, and its favorable performance when compared with outcomes reported for other regimens utilized in RR-AML, we believe enhancing the efficacy of CLAG-M is a rational approach to improve therapy in RR-AML.

A promising approach that could enhance the clearance of leukemic blasts when added to CLAG-M chemotherapy is a monoclonal antibody radioconjugate directed against markers expressed in leukemic cells. Radiation has known cytotoxic properties in chemo-resistant AML. The benefit of an antibody radioconjugate would be leukemic specific delivery of potent radiotherapy with potentially minimal systemic off-target side-effects. One such antibody radioconjugate is Lintuzumab-Ac225, a highly cytotoxic alpha radiation emitter that targets the cluster of differentiation 33 (CD33) cell surface antigen, which is expressed on leukemic cells.

In this novel study, we aim to add the radioconjugated antibody Lintuzumab-Ac225 to salvage CLAG-M chemotherapy in order to improve the treatment response for patients with RR-AML.

• Study Type: Interventional
• Enrollment (Actual): 26
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Froedtert Hospital and the Medical College of Wisconsin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥18 years at the time of informed consent.
2. Morphologically documented primary AML or secondary AML [from prior conditions such as Myelodysplastic Syndrome (MDS), myeloproliferative neoplasm (MPN)] or therapy related AML (t-AML), as defined by World Health Organization (WHO) criteria.
3. In first or subsequent relapse or refractory status after prior therapy, with or without prior hematopoietic stem cell transplant (HSCT). Patients with MDS and progression to AML on hypomethylating agents will also be included.
4. Eastern Cooperative Oncology Group (ECOG) performance score 0-2.
5. Greater than 25% of blasts must be CD33 positive on flow cytometry using Phycoerythrin (PE) labeled anti-CD33 antibody.

6. Patients must meet the following clinical laboratory criteria:

   • Total bilirubin ≤ 2 x the upper limit of the normal range (ULN)
   • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.
   • Calculated creatinine clearance ≥ 50 mL/min
   • Resting left ventricular ejection fraction (LVEF) > 40%
7. Female patients must agree to avoid becoming pregnant, and male patients should avoid impregnating a female partner.

Exclusion Criteria:

1. Acute Promyelocytic Leukemia.
2. Active severe infection not well controlled by antibacterial or antiviral therapy.
3. Known infection with human immunodeficiency virus.
4. Patients with documented pulmonary disease, with a diffusing capacity of the lungs for carbon monoxide (DLCO) and/or forced expiratory volume in one second (FEV1) <65%, or history of dyspnea at rest, or requiring oxygen.
5. Pregnant or breast feeding women.
6. Prior chemotherapy or radiotherapy within 14 days of study entry unless fully recovered from adverse effects due to treatment, at investigator's discretion.
7. Active malignancy within 2 years of entry, except previously treated melanoma grade 2 or less, non-melanoma skin cancer, carcinoma in situ, or cervical intraepithelial neoplasia, and organ confined prostate cancer with no evidence of progressive disease based on prostate-specific antigen (PSA) levels and are not on active therapy. Active malignancy is malignancy receiving treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab); Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.	Biological: Lintuzumab-Ac-225 (Dose 1: 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab); Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.; Other Names: HuM195-Ac225; Actimab-A; Drug: Cladribine; Cladribine 5mg/m^2/day IV over two hours on days 2-6.; Other Names: Leustatin; Mavenclad; Drug: Cytarabine; Cytarabine 2 gm/m^2/day IV over four hours on days 2-6.; Other Names: Cytosar-U; Depocyt; cytosine arabinoside (ara-C); Drug: Mitoxantrone; Mitoxantrone 10mg/m^2/day IV on days 2-4.; Other Names: Mitozantrone; Novantrone; Drug: G-CSF; G-CSF at a dose of 300 µg on days 1-6.; Other Names: colony-stimulating factor 3 (CSF 3)
Experimental: Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab); Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.	Drug: Cladribine; Cladribine 5mg/m^2/day IV over two hours on days 2-6.; Other Names: Leustatin; Mavenclad; Drug: Cytarabine; Cytarabine 2 gm/m^2/day IV over four hours on days 2-6.; Other Names: Cytosar-U; Depocyt; cytosine arabinoside (ara-C); Drug: Mitoxantrone; Mitoxantrone 10mg/m^2/day IV on days 2-4.; Other Names: Mitozantrone; Novantrone; Drug: G-CSF; G-CSF at a dose of 300 µg on days 1-6.; Other Names: colony-stimulating factor 3 (CSF 3); Biological: Lintuzumab-Ac-225 (Dose 2: 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab); Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.; Other Names: HuM195-Ac225; Actimab-A
Experimental: Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab); Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.	Drug: Cladribine; Cladribine 5mg/m^2/day IV over two hours on days 2-6.; Other Names: Leustatin; Mavenclad; Drug: Cytarabine; Cytarabine 2 gm/m^2/day IV over four hours on days 2-6.; Other Names: Cytosar-U; Depocyt; cytosine arabinoside (ara-C); Drug: Mitoxantrone; Mitoxantrone 10mg/m^2/day IV on days 2-4.; Other Names: Mitozantrone; Novantrone; Drug: G-CSF; G-CSF at a dose of 300 µg on days 1-6.; Other Names: colony-stimulating factor 3 (CSF 3); Biological: Lintuzumab-Ac-225 (Dose 3: 0.75 μCi/kg with 4.7μg/kg lintuzumab); Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.; Other Names: HuM195-Ac225; Actimab-A
Experimental: Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab); Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.	Drug: Cladribine; Cladribine 5mg/m^2/day IV over two hours on days 2-6.; Other Names: Leustatin; Mavenclad; Drug: Cytarabine; Cytarabine 2 gm/m^2/day IV over four hours on days 2-6.; Other Names: Cytosar-U; Depocyt; cytosine arabinoside (ara-C); Drug: Mitoxantrone; Mitoxantrone 10mg/m^2/day IV on days 2-4.; Other Names: Mitozantrone; Novantrone; Drug: G-CSF; G-CSF at a dose of 300 µg on days 1-6.; Other Names: colony-stimulating factor 3 (CSF 3); Biological: Lintuzumab-Ac-225 (Dose 4: 1.00 μCi/kg with 6.4 μg/kg lintuzumab); Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.; Other Names: HuM195-Ac225; Actimab-A
Experimental: Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab); Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.	Drug: Cladribine; Cladribine 5mg/m^2/day IV over two hours on days 2-6.; Other Names: Leustatin; Mavenclad; Drug: Cytarabine; Cytarabine 2 gm/m^2/day IV over four hours on days 2-6.; Other Names: Cytosar-U; Depocyt; cytosine arabinoside (ara-C); Drug: Mitoxantrone; Mitoxantrone 10mg/m^2/day IV on days 2-4.; Other Names: Mitozantrone; Novantrone; Drug: G-CSF; G-CSF at a dose of 300 µg on days 1-6.; Other Names: colony-stimulating factor 3 (CSF 3); Biological: Lintuzumab-Ac-225 (Dose 5: 1.25 μCi/kg with 8.0 μg/kg lintuzumab); Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.; Other Names: HuM195-Ac225; Actimab-A
Experimental: Lintuzumab Ac225 Recommended Phase 2 Dose (RP2D); The maximum-tolerated dose for lintuzumab-Ac225 is defined as the highest level at which no more than one patient experiences a dose-limiting toxicity. The RP2D is defined as the dose level below the dose where two or more dose-limiting toxicities were observed. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.	Drug: Cladribine; Cladribine 5mg/m^2/day IV over two hours on days 2-6.; Other Names: Leustatin; Mavenclad; Drug: Cytarabine; Cytarabine 2 gm/m^2/day IV over four hours on days 2-6.; Other Names: Cytosar-U; Depocyt; cytosine arabinoside (ara-C); Drug: Mitoxantrone; Mitoxantrone 10mg/m^2/day IV on days 2-4.; Other Names: Mitozantrone; Novantrone; Drug: G-CSF; G-CSF at a dose of 300 µg on days 1-6.; Other Names: colony-stimulating factor 3 (CSF 3); Biological: Lintuzumab-Ac-225 (Recommended Phase 2 Dose); The maximum-tolerated dose for lintuzumab-Ac225 is defined as the highest level at which no more than one patient experiences a dose-limiting toxicity. The RP2D is defined as the dose level below the dose where two or more dose-limiting toxicities were observed. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.; Other Names: HuM195-Ac225; Actimab-A

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The number of subjects with dose-limiting toxicities.	Dose-escalation will be conducted according to a 3+3 design with a five-patient expansion cohort at the recommended phase 2 dose. The initial dose of Lintuzumab-Ac225 will be 0.25 micro-Curie (μCi)/kg (Dose level 1), and the highest dose administered will be 1.25 μCi/kg.; if 0/3 pts have no dose-limiting toxicity (DLT), new patients enter next dose level.; if 1/3 pts has DLT, 3 pts treated at same dose level.; if 0/3 pts at that dose level has DLT, new pts enter higher level.; if 1 or more of the additional 3 pts has a DLT, no further pts started at dose level, preceding dose is the MTD.; if 2/3 of initially dosed patients have a DLT on first dose, study terminated.; if 0/3 have DLT at highest dose, additional 3 enrolled.	28 Days
Maximum-tolerated dose.	Defined as the dosage with the highest level at which no more than one subject experiences a DLT.	28 Days
The number of subjects who have at least one serious adverse event related to the study.	All subjects who receive study drug will be closely monitored for serious adverse events (SAEs). The NCI's CTCAE (Common Toxicity Criteria for Adverse Effects) v4.03 will be used.	60 days
Overall survival	The number of subjects alive at two years from the first day of salvage therapy.	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The number of subjects with a complete response (CR).	A complete response will be defined as bone marrow blasts <5% with absolute neutrophil count ≥1000/μL and platelet ≥100,000/μL.	Up to Day 60
The number of subjects with CR with incomplete hematologic recovery (CRi)	CRi is defined as CR without platelet recovery or neutrophil recovery. This will be defined as bone marrow blasts <5% with absolute neutrophil count <1000/L and platelet <100,000/L.	Up to Day 60
The number of subjects in a morphologic leukemia-free state (MLFS).	MLFS is bone marrow blasts <5% with absolute neutrophil count <1000/μL AND platelet <100,000/μL.	Up to Day 60
The number of subjects experiencing partial remission.	Partial remission (PR) is defined by a decrease of at 50% or more in the percentage of blasts to less than 25% in the bone marrow. and normalized blood counts ( ANC>1000, Platelets>100,000/ml).	Up to Day 60
Progression-free Survival	The number of subjects, who from the first day of remission until one year, do not relapse or progress.	1 Year

Collaborators and Investigators

• Sponsor: Medical College of Wisconsin
• Investigators: Principal Investigator: Sameem Abedin, MD, Medical College of Wisconsin

Study record dates

Study Major Dates

• Study Start (Actual): May 22, 2018
• Primary Completion (Estimated): May 20, 2024
• Study Completion (Estimated): October 1, 2024

Study Registration Dates

• First Submitted: February 15, 2018
• First Submitted That Met QC Criteria: February 15, 2018
• First Posted (Actual): February 22, 2018

Study Record Updates

• Last Update Posted (Actual): November 18, 2023
• Last Update Submitted That Met QC Criteria: November 16, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: Acute myeloid leukemia; Relapsed/refractory acute myeloid leukemia; CLAG-M; Lintuzumab
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Peripheral Nervous System Agents; Antiviral Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antineoplastic Agents, Immunological; Adjuvants, Immunologic; Lenograstim; Cytarabine; Mitoxantrone; Cladribine; Lintuzumab
• Other Study ID Numbers: PRO00031633

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No